Summary:
In patients with type 2 diabetes, enavogliflozin treatment over 24 weeks significantly reduced leptin levels and improved insulin resistance compared to placebo treatment, though it was associated with no significant adverse effects directly reported in this post hoc analysis.
| PICO | Description |
|---|---|
| Population | Adult patients diagnosed with type 2 diabetes enrolled in a randomized, double-blind, placebo-controlled phase III clinical trial. |
| Intervention | Enavogliflozin treatment administered over a period of 24 weeks. |
| Comparison | Placebo group matched over the same 24-week duration as part of the controlled trial. |
| Outcome | Enavogliflozin significantly reduced leptin levels (LS mean difference: -2.99 µg/L) independent of weight change, and this reduction correlated with improvements in insulin resistance and increases in serum ketone levels. Adiponectin levels also increased, but this effect was not significant after adjusting for weight change. |
Source: Young Sang Lyu, et al. “Weight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes.” Read article here.
